| Comprehensive evaluation of programmed death-ligand 1 expression in primary and metastatic prostate cancer MC Haffner, G Guner, D Taheri, GJ Netto, DN Palsgrove, Q Zheng, ... The American journal of pathology 188 (6), 1478-1485, 2018 | 146 | 2018 |
| MSH2 loss in primary prostate cancer LB Guedes, ES Antonarakis, MT Schweizer, N Mirkheshti, F Almutairi, ... Clinical cancer research 23 (22), 6863-6874, 2017 | 146 | 2017 |
| Genomic characterization of prostatic ductal adenocarcinoma identifies a high prevalence of DNA repair gene mutations MT Schweizer, ES Antonarakis, TA Bismar, LB Guedes, HH Cheng, ... JCO precision oncology 3, 1-9, 2019 | 86 | 2019 |
| Analytic validation of a clinical-grade PTEN immunohistochemistry assay in prostate cancer by comparison with PTEN FISH TL Lotan, W Wei, O Ludkovski, CL Morais, LB Guedes, T Jamaspishvili, ... Modern Pathology 29 (8), 904-914, 2016 | 86 | 2016 |
| Association of tumor-infiltrating T-cell density with molecular subtype, racial ancestry and clinical outcomes in prostate cancer HB Kaur, LB Guedes, J Lu, L Maldonado, L Reitz, JR Barber, ... Modern Pathology 31 (10), 1539-1552, 2018 | 85 | 2018 |
| Analytic, Preanalytic, and Clinical Validation of p53 IHC for Detection of TP53 Missense Mutation in Prostate Cancer LB Guedes, F Almutairi, MC Haffner, G Rajoria, Z Liu, S Klimek, R Zoino, ... Clinical Cancer Research 23 (16), 4693-4703, 2017 | 77 | 2017 |
| p53 status in the primary tumor predicts efficacy of subsequent abiraterone and enzalutamide in castration-resistant prostate cancer BL Maughan, LB Guedes, K Boucher, G Rajoria, Z Liu, S Klimek, R Zoino, ... Prostate cancer and prostatic diseases 21 (2), 260-268, 2018 | 58 | 2018 |
| PTEN loss in Gleason score 3+ 4= 7 prostate biopsies is associated with nonorgan confined disease at radical prostatectomy LB Guedes, JJ Tosoian, J Hicks, AE Ross, TL Lotan The Journal of Urology 197 (4), 1054-1059, 2017 | 44 | 2017 |
| ERG and PTEN status of isolated high-grade PIN occurring in cystoprostatectomy specimens without invasive prostatic adenocarcinoma CL Morais, LB Guedes, J Hicks, AS Baras, AM De Marzo, TL Lotan Human pathology 55, 117-125, 2016 | 43 | 2016 |
| TP53 missense mutation is associated with increased tumor-infiltrating T cells in primary prostate cancer HB Kaur, J Lu, LB Guedes, L Maldonado, L Reitz, JR Barber, ... Human pathology 87, 95-102, 2019 | 41 | 2019 |
| Analytic Validation of RNA In Situ Hybridization (RISH) for AR and AR-V7 Expression in Human Prostate Cancer LB Guedes, CL Morais, F Almutairi, MC Haffner, Q Zheng, JT Isaacs, ... Clinical Cancer Research 22 (18), 4651-4663, 2016 | 40 | 2016 |
| Risk stratification of prostate cancer through quantitative assessment of PTEN loss (qPTEN) T Jamaspishvili, PG Patel, Y Niu, T Vidotto, I Caven, R Livergant, W Fu, ... JNCI: Journal of the National Cancer Institute 112 (11), 1098-1104, 2020 | 26 | 2020 |
| CDKN1B Deletions are Associated with Metastasis in African American Men with Clinically Localized, Surgically Treated Prostate Cancer FA Faisal, S Murali, H Kaur, T Vidotto, LB Guedes, DC Salles, V Kothari, ... Clinical Cancer Research 26 (11), 2595-2602, 2020 | 21 | 2020 |
| PTEN status assessment in the Johns Hopkins active surveillance cohort JJ Tosoian, LB Guedes, CL Morais, M Mamawala, AE Ross, AM De Marzo, ... Prostate cancer and prostatic diseases 22 (1), 176-181, 2019 | 16 | 2019 |
| PTEN Loss with ERG Negative Status is Associated with Lethal Disease after Radical Prostatectomy NM Haney, FA Faisal, J Lu, LB Guedes, VE Reuter, HI Scher, JA Eastham, ... The Journal of urology 203 (2), 344-350, 2020 | 14 | 2020 |
| Validation of long mononucleotide repeat markers for detection of microsatellite instability JH Lin, S Chen, A Pallavajjala, LB Guedes, TL Lotan, JW Bacher, ... The Journal of Molecular Diagnostics 24 (2), 144-157, 2022 | 13 | 2022 |
| Somatic molecular subtyping of prostate tumors from HOXB13 G84E carriers TL Lotan, A Torres, M Zhang, JJ Tosoian, LB Guedes, H Fedor, J Hicks, ... Oncotarget 8 (14), 22772, 2017 | 11 | 2017 |
| Effect of preanalytic variables on an automated PTEN immunohistochemistry assay for prostate cancer LB Guedes, CL Morais, H Fedor, J Hicks, B Gurel, J Melamed, P Lee, ... Archives of Pathology & Laboratory Medicine 143 (3), 338-348, 2019 | 9 | 2019 |
| Assessment of MYC/PTEN status by gene-protein assay in grade group 2 prostate biopsies DC Salles, T Vidotto, FA Faisal, JJ Tosoian, LB Guedes, A Muranyi, I Bai, ... The Journal of Molecular Diagnostics 23 (8), 1030-1041, 2021 | 3 | 2021 |
| Genomic characterization of ductal adenocarcinoma of the prostate. MT Schweizer, ES Antonarakis, TA Bismar, L Guedes, HH Cheng, ... Journal of Clinical Oncology 36 (15_suppl), 5030-5030, 2018 | 2 | 2018 |
